Michael Fanelli
Nurse Practitioner · Chicago, ILNPI 1770106965
Payments from drug & device makers
Across 183 payments — averaging $21.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$1K
- Gilead$1K
- Merck$458
- Janssen Products, LP$199
- Novo Nordisk$188
- Johnson & Johnson$176
- plus $697 from 14 others
What the payments were for
- Food & beverage$3,77794%
- Education$2276%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 57 | $1,169 |
| Gilead | 53 | $1,117 |
| Merck | 18 | $458 |
| Janssen Products, LP | 2 | $199 |
| Novo Nordisk | 8 | $188 |
| Johnson & Johnson(2 entities) | 8 | $176 |
| AbbVie | 8 | $159 |
| Amgen | 4 | $83 |
| Theratechnologies Inc. | 3 | $70 |
| Antares Pharma, Inc. | 4 | $67 |
| GSK | 3 | $49 |
| Lilly USA, LLC | 3 | $48 |
| Napo Pharmaceuticals Inc | 2 | $42 |
| Dynavax Technologies Corporation | 3 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Alkermes, Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Pfizer | 1 | $17 |
How this compares
$4,004 in reported general payments places this provider in the 90th percentile of 4,869 nurse practitioner providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 56 | $238,877 |
| DescovyEmtricitabine/Tenofov Alafenam | 74 | $183,433 |
| JulucaDolutegravir/Rilpivirine | 12 | $49,134 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 11 | $39,152 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $562 |
| Doxycycline Hyclate | 11 | $516 |
| Rosuvastatin Calcium | 12 | $440 |
| Gabapentin | 20 | $388 |
| Atorvastatin Calcium | 36 | $345 |
| Amlodipine Besylate | 12 | $188 |
| ValacyclovirValacyclovir Hcl | 12 | $155 |
| Tamsulosin Hcl | 12 | $128 |
| Estradiol | 12 | $127 |
| Lisinopril | 16 | $107 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $1,117 | $422,310130 claims |
| Viiv Healthcare CompanyJuluca, Triumeq | $1,169 | $88,28523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,869 nurse practitioner providers in Illinois.
Other nurse practitioner in Chicago
- Erika VuckoChicago$417K
- Kristy LukeChicago$77K
- Michelle MunroeChicago$64K
- Melanie SamardzijaChicago$42K
- Rana KennellyChicago$42K
- Fiona LynnChicago$41K
- Melissa DuckettChicago$30K
- Allison MorinChicago$27K
- Christy DavisChicago$19K
- Ariel HughChicago$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.